| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD22 molecule | ||||
| GTO ID | GTC3081 |
| Trial ID | NCT05429905 |
| Disease | Acute Lymphoblastic Leukemia |
| Altered gene | CD22|CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CAR-T2219.1 |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia |
| Year | 2022 |
| Country | Singapore |
| Company sponsor | KK Women's and Children's Hospital |
| Other ID(s) | CART2219-1.0 |
| Cohort 1 | |||||||||
|
|||||||||